12:01 PM EST - Oncolytics Biotech Inc. : announced that it has completed patient enrollment in its U.S. Phase I clinical trial using REOLYSIN in combination with FOLFIRI (Folinic Acid (leucovorin) with Fluorouracil (5-FU) and Irinotecan) in patients with oxaliplatin refractory, Kras mutant colorectal cancer. Oncolytics Biotech Inc.
shares T.ONC are trading down $0.03 at $3.02.
